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Background: Chemotherapy and targeted agent anti-cancer efficacy is largely dependent on the proliferative
state of tumours, as exemplified by agents that target DNA synthesis/replication or mitosis. As a result, cell
cycle specificities of a number of cancer drugs are well known. However, they are yet to be described in a
quantifiable manner.
Methods: A scalable cell synchronisation protocol used to screen a library of 235 anti-cancer compounds
exposed over six hours in G1 or S/G2 accumulated AsPC-1 cells to generate a cell cycle specificity (CCS) score.
Findings: The synchronisation method was associated with reduced method-related cytotoxicity compared to
nocodazole, delivering sufficient cell cycle purity and cell numbers to run high-throughput drug library
screens. Compounds were identified with G1 and S/G2-associated specificities that, overall, functionally
matched with a compound's target/mechanism of action. This annotation was used to describe a synergistic
schedule using the CDK4/6 inhibitor, palbociclib, prior to gemcitabine/AZD6738 as well as describe the corre-
lation between the CCS score and published synergistic/antagonistic drug schedules.
Interpretation: This is the first highly quantitative description of cell cycle-dependent drug sensitivities that
utilised a tractable and tolerated method with potential uses outside the present study. Drug treatments
such as those shown to be G1 or S/G2 associated may benefit from scheduling considerations such as after
CDK4/6 inhibitors and being first in drug sequences respectively.
Funding: Cancer Research UK (CRUK) Institute core grants C14303/A17197 and C9545/A29580. The Li Ka
Shing Centre where this work was performed was generously funded by CK Hutchison Holdings Limited, the
University of Cambridge, CRUK, The Atlantic Philanthropies and others.
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The interplay between cancer and the cell cycle is well known,
with amplification of mitogenic signals through oncogenes such as c-
Myc and phosphoinositide 3-kinases (PI3Ks) and loss of tumour sup-
pressors like p53, p21 and pRb converging to promote uncontrolled
proliferation [1]. Yet, in the context of cancer therapy, exploitation of
this connection to improve the therapeutic index of treatments out-
side the basic anti-proliferative mechanism of chemotherapy is
somewhat limited. Such methods, broadly termed “cyclotherapy”,have been of interest for some time but have yet to break into signifi-
cant use likely due to both biological and clinical complexities [2].
However, the interplay between cell cycle and drug activity, particu-
larly in combination therapy, has important consequences when con-
sidering drug synergy or antagonism [3]. The most prototypical
example of cell cycle dependency is the scheduling effects seen with
microtubule poisons such as paclitaxel that are most potent during
mitosis. Many agents including platinum-based chemotherapies as
well as non-specific and specific cyclin-dependent kinase (CDK)
inhibitors have all been shown to antagonise paclitaxel activity when
given concurrently or as the first drug in a schedule due to the nega-
tive impact of these drugs on progression through M phase [4-6].
Despite promising pre-clinical data, early efforts to utilise pan-
CDK inhibitors such as flavopiridol in combinations were typically
hampered by a low therapeutic index due to low anti-tumour
Research in Context
Evidence before this study
Drug combinations and drug scheduling are increasingly being
employed to combat the lack of efficacy or development of
drug resistance often observed in cancer treatment. The cell
cycle is well known to not only play a role in tumour formation
but also in treatment response where previous attempts at
combining cell cycle inhibitors with standard chemotherapies
have given mixed outcomes.
Added value of this study
This study describes a better tolerated, scalable synchronisation
method used to interrogate cell cycle dependencies of anti-can-
cer compounds. This phenotypic annotation was utilised to
describe a novel and productive combination of sequential cell
cycle treatments as well as implicate cell cycle specificity with
scheduling antagonism using an external dataset.
Implications of all the available evidence
Understanding cell cycle specificities of anti-cancer compounds
may aid selection of productive combinations and schedules
and further exploration as a routine metric used in pre-clinical
drug development may be warranted.
2 T.I. Johnson et al. / EBioMedicine 68 (2021) 103396efficacies and major off-target toxicities, particularly neutropenia and
thrombocytopenia [7]. However, there has been a resurgence in
interest in this class of agents with the advent of third generation
CDKi's, such as palbociclib, ribociclib and abemaciclib, that target
non-conserved ATP binding pockets and exhibit higher selectivity
alongside fewer dose-limiting toxicities [8,9]. Even so, combination
as well as scheduling of these inhibitors with traditional chemothera-
pies has produced mixed cellular responses with both synergistic and
antagonistic interactions being observed [10-12]. This contrasts with
the promising combination of CDK4/6 compounds with inhibitors
whose targets are associated with mitogenic signalling in G1 phase,
such as mammalian target of rapamycin (mTOR) inhibitors [13-16],
where the cell cycle-dependent potencies of each drug may be mech-
anistically complementary. Given the importance of combination
therapy and drug scheduling in cancer treatment, alongside these
complex cell cycle interactions, the ability to quantify these broad G1
and S/G2/M cell cycle phase dependencies may better inform treat-
ment strategies.
Many key cell cycle processes have been uncovered using meth-
ods that induce synchronous cell cycle progression and as such have
helped form the basis of our understanding of this complex system.
However, there are both biological and technical caveats associated
with these methods. Chemical synchronisation approaches are often
associated with a negative impact on proliferation/survival and
increased DNA damage such as that seen with microtubule poisons
(e.g. nocodazole) [17,18], as well as those that disrupt DNA replica-
tion including hydroxyurea and thymidine [19,20]. Use of fluorescent
cell cycle reporters, such as those used in the FUCCI system [21], has
bypassed these issues to some extent by avoiding synchronisation
but its use is generally limited to low-throughput assays due to inten-
sive live cell imaging and low cell numbers. Based on these technical
limitations, use of a tolerated and high-yield method was paramount
in order to tackle the question of cell cycle-dependent drug sensitivi-
ties. Agents used in G2/M synchronisation methods result in subse-
quent G1/S/G2 populations that occur in the absence of the arresting
agent, better mimicking unperturbed cell cycle progression. Despite
its limitations, nocodazole is widely used to induce prometaphase
mitotic arrest and is often coupled with a mechanical detachment (amitotic shake-off) to produce highly pure mitotic fractions [19]. The
CDK1 inhibitor RO-3306, was first described as a reversible inducer
of G2/M arrest with synchronous entry into M phase upon inhibitor
withdrawal and demonstrated potential to be combined with a
shake-off method [22].
In this study, we describe a better tolerated, efficient and scalable
synchronisation method using the reversible CDK1 inhibitor RO-
3306. This method was used to screen a library of over 200 anti-can-
cer compounds to generate a cell cycle specificity score based on rela-
tive drug activity between G1 and S/G2 accumulated states. This cell
cycle specificity was explored further in the context of a published
dataset describing effects of sequential drug treatment, revealing cor-
relations with synergistic and antagonistic combinations.
Methods
All experiments were performed using established human cancer
cell lines in vitro using techniques described in the following sections.
Cell culture & chemicals
All cell lines were cultured at 37°C, 5% CO2 for a maximum of 20
passages after thawing and were cultured in DMEM (Thermo Fisher
#41966029) (MIA PaCa-2, PANC-1, HeLa) or RPMI-1640 (Thermo
Fisher #21875034) (AsPC-1) and supplemented with 10% fetal bovine
serum (FBS) (Thermo Fisher #10270106). Murine cell line K8484 were
previously established from KPC mice of 129/SvJae/C57Bl/6 back-
ground and were grown in DMEM supplemented with 5% FBS [23].
Each cell line passed mycoplasma and single tandem repeat (STR) gen-
otyping tests performed internally by the CRUK-CI Cell Services core
facility. RO-3306 (Merck, #217699), nocodazole (Sigma-Aldrich,
#M1404), gemcitabine (Tocris, #3259), CB-5083 (BioVision via Cam-
bridge Bioscience, #B1032-5), palbociclib (Sigma, PZ0199) and SN-38
(Merck, H0165) were dissolved in DMSO, aliquoted and stored at -20°
C. A customised Cambridge Cancer Compound Library (L2300) was
purchased from Selleckchem pre-dissolved in DMSO at 10 mM.
AZD6738 was provided by AstraZeneca.
Cell cycle synchronisation
For nocodazole-based synchronisation, cells were incubated with
100 nM nocodazole for 14 hours before a shake off was performed
using physical agitation of the dish to collect mitotic cells. For the
RO-3306-based method, cells were incubated with 6 mM RO-3306
for 20 hours before being washed three times with 1xPBS, replen-
ished with media and incubated at 37°C/5% CO2 for a further hour. A
shake off was then performed in a similar manner to nocodazole-
treated cells. Cells collected after the shake off were then washed in
1xPBS, spun using a benchtop centrifuge and the pellet suspended in
culture media before re-seeding for downstream analysis. All centri-
fugation steps were performed at 1000 rpm.
Flow cytometry
Cells were collected via trypsinisation at the indicated times,
washed with 1xPBS and fixed in ice-cold 70% ethanol overnight at
-20°C. Fixed cells were then washed once with 1xPBS before being
incubated in 500 mL blocking buffer (1xPBS +2% BSA + 0.1% TritonX-
100/Tween20) for 1 hour at room temperature (RT), primary anti-
body solution (phospho-MPM-2, 1:500, Merck Millipore #05-368;
phospho-histone H2AX S139, 1:500, Merck Millipore #05-636) in
blocking buffer for 2 hours at RT and secondary antibody solution
(Alexa Fluor 488 Goat anti-mouse, 1:500, Thermo Fisher #A11017) in
blocking buffer for 1 hour at RT in the dark with three washes using
blocking buffer between each step. Fixed cells were then incubated
with blocking solution containing the DNA dye FxCycle Violet (1 mg/
T.I. Johnson et al. / EBioMedicine 68 (2021) 103396 3mL, Thermo Fisher #F10347) for at least 1 hour at RT in the dark
before samples were run using the BD Biosciences LSRFortessaTM
flow cytometer and analysed using FlowJo and GraphPad Prism soft-
ware. Gating strategies are outlined in the supplemental material.
Proliferation assays
For colony forming and clonocidal assays, 300 or 120 cells (MIA
PaCa-2, HeLa, PANC-1, MCF7, K8484) and 1000 or 400 cells (AsPC-1)
were seeded in 6 or 12 well plates respectively and grown for 11-
14 days depending on the cell line with the final four days including
drug exposure where indicated. Cells were fixed with 3% trichloro-
acetic acid (TCA) for 30 minutes at 4°C before staining with the pro-
tein dye sulforhodamine B (SRB). Images were then taken and
colonies counted using a GelCountTM (Oxford Optronix) before dis-
solving in 10 mM Tris pH 8.0 solution for fluorescence quantification
using a spectrophotometer. For colony forming assays, plating effi-
ciency was calculated by dividing the number of colonies by the
number of cells seeded, multiplied by 100. SRB and live cell IncuCyte
time lapse experiments using the YOYO-3 viability dye (Thermo
Fisher, #Y3606) were performed in 96-well plates as described previ-
ously [24].
Compound library screen
AsPC-1 cells were synchronised using RO-3306 as described above
and isolated mitotic cells were seeded at 500 cells per well into 384-
well plates using the MultidropTM Combi dispenser (Thermo Fisher).
Each plate consisted of 12 DMSO control wells alongside an 11-point
dose response (from 0.3 nM to 30 mM) for seven compounds with
two replicates for each condition. Four wells were treated with high
dose SN-38 (10 mM) as a positive control to ensure no technical
issues with dosing was observed. Compound was added using the
LabCyte Echo 555 acoustic dispenser in a randomised well layout at
4 hours post-seeding for G1max and 18 hours post-seeding for S/
G2max. For pulse treatment, compound-containing media was
removed from the wells, washed with sterile, pre-warmed PBS and
fresh media added using a combination of the Integra Viaflo 384
benchtop electronic pipette system and the MultidropTM Combi dis-
penser. Plates were then fixed with 4% formaldehyde at 96 hours
post-drug addition, stained with 1 mg/mL Hoechst 33342 (Thermo
Fisher, #H3570) and nuclei counted using the CellInsight NXT
(Thermo Fisher). Each condition was normalised to the mean DMSO
value within the same plate and non-linear regression fitted to the
dose response (log[inhibitor] vs response  variable slope, GraphPad
Prism 8). The area under the curve (AUC) was then calculated for
each dose response and compared between cell cycle conditions. By
modifying the relative change/fractional difference formula [B/A]-1
we calculated cell cycle specificity score (CCS) as CCS = 1-(AUC[MIN]/
AUC[MAX]) to generate a consistent fold change metric with a value
of 0 denoting no change. If the AUC[MIN] was in the G1-accumulated
condition the score was transformed by multiplying by -1 such that a
compound with a score >0 suggested more S/G2 specificity and <0
suggested more G1 specificity.
Statistics
Data is reported as mean with § SEM or SD, detailed in the figure
legend as applicable, of at least three independent biological repli-
cates except for Figure 2 and 5 describing the compound library
screen and scheduling comparison respectively where sample size is
detailed in the figure legends. Statistical analysis of two parameters
was performed using either a two-tailed, unpaired t test (Figure 1d),
or two-tailed, unpaired Mann-Whitney test (Figure 4d/e) based on
data distribution. Standard deviations were not assumed to be equal.
For multiple comparisons involving more than two parameters, amultiple unpaired t test with Holm-Sidak multiple comparisons cor-
rection (Figure 1b) or a one-way or two-way ANOVA was performed
with a Bonferroni correction (Figure 3b, 4d/f) were performed. A
Gaussian non-linear regression was used with a least-squares fit for
frequency distributions. P values that were <0.05 (two-sided) were
considered statistically significant for all statistical calculations. Com-
parisons with non-significant p-values >0.05 were not displayed on
all figures for better clarity. PRISM 8.4.0 (GraphPad Software, San
Diego, CA, USA) was used for data analysis.
Role of funding source
The funders of this study had no role in study design, data collec-
tion, data analyses, interpretation, or writing of the report.
Results
An RO-3306 based mitotic shake off protocol produces pure fractions
with improved viability
To assess the utility of an RO-3306 shake off protocol in producing
synchronised cell fractions we first exposed the pancreatic adenocar-
cinoma (PDAC) cell line, AsPC-1, to increasing concentrations of RO-
3306. After flow cytometry-based cell cycle analysis using DNA con-
tent and a mitotic marker, the minimum concentration needed for
maximal G2 arrest was 6 mM after 20 hours (Figure S1). Subsequent
analysis of mitotic entry after RO-3306 release, mitotic shake-off and
subsequent G1 entry post re-seeding indicated that this method pro-
duced highly pure mitotic and G1 fractions with minimal contamina-
tion from other phases (Figure 1a). The increase in the mitotic
fraction between RO-3306 released cells and the shake off demon-
strates the added benefit of including this mechanical detachment
step within the method. Both mitotic accumulation after shake-off
and subsequent G1 entry improved using the RO-3306-based method
compared to a standard nocodazole-based mitotic shake off protocol
(Figure 1b). Importantly, mitotic cells isolated using the RO-3306
based method demonstrated improved long-term proliferative
capacity compared to nocodazole as assessed by clonogenic assay
(Figure 1c), as well as improved viability after re-seeding post shake-
off as demonstrated by the increase in a cell death marker, YOYO-3
staining, in live cell imaging assays (Figure 1d). This method was also
tested after optimisation in three other cell lines; HeLa, MIA PaCa-2
and Panc-1 cells (Figure 1e). The RO-3306 based method consistently
increased G1 purity post-shake off compared to nocodazole across all
tested cell lines. Given the purity of the mitotic population, AsPC-1
cells were taken forward to characterise further. To assess down-
stream synchronisation post-mitosis, cells were re-seeded into dishes
and collected at 3-hour intervals. Using DNA content and a mitotic
marker, we found AsPC-1 cells exhibited a moderately static 2N pop-
ulation from 4-12 hours post-seeding suggesting minimal DNA repli-
cation during these time points (Figure 1f). From 12 hours onwards,
we could detect a time dependent increase in >2N DNA content that
was maximal by 18 hours post-seeding (Figure 1f). As expected, the
percentage of mitotic cells remained low after re-seeding with some
evidence of mitotic entry by 24h (Figure 1f). A summary of the final
method is shown in Figure 1g. Additionally, as HeLa cells are com-
monly used in synchronisation assays, downstream synchronisation
of HeLa cells after the same method was also tested (Figure S2) dem-
onstrating the potential utility of this method outside the present
study.
The synchronisation method is amenable to higher throughput drug
screening approaches
The described method was ideally suited to address the question
of cell cycle dependent drug sensitivities based on the purity of the
Figure 1. Characterisation of the RO-3306 shake off method. a. Cell cycle quantification using DNA content and a mitotic marker, phospho-MPM2, after flow cytometry analysis
of cells treated with DMSO or after a nocodazole (noc.) or RO-3306-based mitotic shake off. SO, shake-off. Release = 1 hour after RO-3306 washout. Re-seed condition used isolated
mitotic cells harvested 3h post-seeding. b. Same quantification as in a highlighting mitotic or G1 content of shake-off or re-seeded cells respectively after nocodazole or RO-3306
treatment. c. Plating efficiency and Sulforhodamine B (SRB) quantification alongside representative images of cell colonies grown after either a nocodazole or RO-3306-based
mitotic shake off. d. Live cell imaging quantification of YOYO-3+ve objects normalised to total growth area. e. Repeat of a-d in three other cell lines, HeLa, MIA PaCa-2 and PANC-1. f.
Cell cycle quantification of G1, S+G2 and M phases using DNA content and the mitotic marker, phospho-MPM2, at given times post-RO-3306 mitotic shake off. Representative DNA
content histograms for each time point are shown on the right. g. Schematic summarising the method. *= Insufficient cell numbers for analysis. All data shown are means from at
least three independent experiments, with error shown either as SD (a, b, d-f) or SEM (c). Students t tests (c) or multiple t tests (b) with a Holm-SIdak multiple comparisons correc-
tion was performed for comparisons between two groups or more respectively.
4 T.I. Johnson et al. / EBioMedicine 68 (2021) 103396cell cycle fractions and reduced method-induced cytotoxicity. Given
the kinetics of DNA content changes we observed, we selected appro-
priate time points to transiently expose synchronised cells to anti-
cancer compounds for 6 hours between 4-10 hours and 18-24 hourspost-seeding after mitotic shake-off to minimise potential overlap
between cell cycle phases, with the caveat that this short-term expo-
sure could compromise drug potency. Continuous drug exposure was
also included for comparison and plates were fixed 96h after drug
T.I. Johnson et al. / EBioMedicine 68 (2021) 103396 5addition. An 11-point dose response from 0.3 nM to 30 mM was cho-
sen to cover a broad spectrum of drug potencies with each concentra-
tion in duplicate, with well randomisation across the plate and both
negative and positive control wells. Without direct access to large-
scale robotic automation, we optimised an up-scaled method that
utilised semi-automated machinery that permitted the assessment of
cell cycle drug-sensitivities in a medium throughput fashion (Figure
S3). Although each aspect of this optimisation was integral, drug
washout using the Integra Viaflo benchtop pipette system was partic-
ularly crucial as we demonstrated this method was the least disrup-
tive to cells but maintained throughput with minimal variability,
compared to manual multichannel pipetting or using a plate washer
(Figure S3c). Considering the scale of through-put we could achieve,
we used a custom commercial drug library containing 231 well-
known anti-cancer compounds covering 15 different pathways (Sell-
eckchem, Table S1). An additional 4 drugs obtained separately to the
commercial library were added to give a total of 235 compounds.
Comparison of area under the curve (AUC) using a fitted dose
response curve was chosen as the most effective assessment of cell
cycle-dependent effects, given that it did not rely on reaching 50%
growth inhibition as needed for GI50 although the two measures are
linked. To compare AUC values between the conditions, we used a
fractional difference metric to calculate a cell cycle specificity (CCS)
score and was defined as 1-(AUC[MIN]/AUC[MAX]) for each com-
pound such that the metric was not biased by order. Finally, if the
AUC[MIN] value was associated with the G1-accumulated condition,
the score was multiplied by minus one to achieve a score where <0
indicated G1 sensitivity and >0 indicated S/G2 sensitivity. The
potency of each drug was also described as the minimum AUC value
of the two cell cycle conditions (AUCmin), allowing assessment of
drug activity over 6 hours of drug exposure.
High throughput compound library screen identifies cell cycle
dependencies
The drug library was tested across 44 separate 384-well plates
where mean DMSO nuclei counts across plates treated during 4-10h
and 18-24h each exhibited plate-to-plate variability but with coeffi-
cient of variations (CV) of less than 10% (Figure S4a). CCS was calcu-
lated for all 235 compounds and plotted as a frequency distribution
where the data followed a Gaussian distribution with R2=0.98 and
mean/SD values of -0.004 and 0.099 respectively (Figure 2a). Across
all compounds tested we observed 54, 39 and 25 candidates that fell
outside 1.5, 2 and 3 times the standard deviation (s) respectively
indicating “hits”, drugs with cell cycle phase-dependency, at all levels
of stringency (Table S1). Given this distribution of the data, we can
confidently define G1 and S/G2 specificity at CCS scores less than
-0.153 or greater than 0.153 respectively. AUCmin also followed a
Gaussian distribution (R2=0.79) where almost half of all compounds
(112/235) had a value within +/- 10% of 3000, indicating either that
6h exposure at any concentration was insufficient to induce obvious
anti-proliferative effects, or a lack of efficacy in this cellular model
(Figure S4b). Plotting CCS against AUCmin identified compounds that
possessed both high potency as a pulse and cell cycle phase specific-
ity (Figure 2b). A correlation was observed between AUCmin and CCS
score although the correlation coefficient was low and reduced fur-
ther when only considering compounds with an AUCmin of less than
2000 (Figure S4c, R2= 0.49 & 0.22). This suggested that, although
there was a correlation between these two factors, AUCmin (i.e.
potency) was a poor predictor of CCS score. This is exemplified by
drugs such as ispinesib, a kinesin spindle protein inhibitor, that dis-
played high potency (AUCmin = 229) but no cell cycle specificity
(CCS = 0.15), contrary to other mitotic drugs such as paclitaxel
(CCS = 0.28, AUCmin = 266; Table S1). When drugs were clustered
based on the pathway annotation provided by the drug library pro-
vider, pathway dependent cell cycle-based potencies were observedthat seemed to match the broad mechanistic annotation for that class
of compounds (Figure 2c), given they are an average score they are
typically lower than those seen for individual compounds. For
instance, the “DNA damage” and “Cell cycle” pathways contain classi-
cal chemotherapies and checkpoint kinase inhibitors respectively,
consistent with their average CCS scores of 0.16 and 0.17 as being S/
G2 specific. Further breakdown of these two pathways identifies the
main drivers behind these scores such as Checkpoint kinase (Chk) 1/2
and Wee1 kinase inhibitors (Cell cycle) as well as topoisomerase and
DNA/RNA synthesis inhibitors (DNA damage, Figure 2d/f). Despite
the “Angiogenesis” pathway having an S/G2-related CCS score, closer
examination of hits identified ENMD-2076, a pan-kinase inhibitor
known to inhibit Aurora A (AurA) kinase, as significantly contributing
to the overall score (Figure 2e). On the opposite end of the spectrum,
both “PI3K/Akt/mTOR” and “MAPK” pathways displayed lower aver-
age CCS scores of -0.06 and -0.10 respectively demonstrating more
G1-associated sensitivity, with mTOR complex 1/2 (mTORC1/2)
inhibitors AZD8055 and sapanisertib having top CCS scores
(Figure 2g/h). Dissection of cell cycle specificity by target identified a
spectrum of CCS and AUCmin values indicating, at least in this cell
line, that there may be differences in cell cycle specificity between
molecules that have the same target. For example, cladribine and clo-
farabine are both purine analogues that broadly disrupt DNA/RNA
synthesis but have different CCS scores (0.17 and 0.73, Table S1). Sim-
ilar observations could be made when comparing mTORC1 inhibitors
temsirolimus (CCS -0.11) and everolimus (-0.06) versus dual
mTORC1/2 inhibitors AZD8055 (-0.37) and sapanisertib (-0.30), with
the latter exhibiting higher specificity to G1 accumulated cells (Table
S1). Visual inspection of dose response curves generated for selected
G1 and S/G2 associated compounds matched the CCS annotation
(Figure 3a). Furthermore, in cases where GI50 calculations were possi-
ble, a number of S/G2-associated compounds demonstrated log fold
changes in GI50 concentrations between cell cycle phases. Consistent
with lower potency scores, changes with G1-associated compounds
were less striking although given the duration of drug exposure and
proposed mechanisms of action this is perhaps not surprising. CCS
scores averaged over three biological triplicates were found to be sta-
tistically significant, showing the robustness of the method and anal-
ysis pipeline (Figure 3b). Comparison of GI50 and CCS scores in the
continuous treatment condition highlighted the impact of drug
washout on potency and also the ability to identify cell cycle specific
hits at higher degrees of confidence (Figure S4c/d). Only 5 com-
pounds were outside the 3s threshold and each of these displayed
low AUC values that did not correspond to a significant shift in GI50
values (Table S1). Surprisingly, we did find compounds which were
just as potent in either pulse or continuous treatment after synchro-
nisation (e.g. rabusertib) suggesting these compounds are active with
short exposure times. Importantly, similar levels of cell cycle syn-
chronisation were observed between the independent biological rep-
licates (Figure S5). Overall, these results demonstrated that cell cycle-
dependent drug sensitivities could be quantified, broadly matched
known cell cycle-dependent mechanisms but also highlighted differ-
ences in sensitivities of compounds with the same target that could
not be explained by drug potency.
Transient G1 phase accumulation accentuates gemcitabine/AZD6738
efficacy
Previous work from our lab identified synergy between gemcita-
bine and an ATR inhibitor, AZD6738, in human and mouse models of
pancreatic cancer in vitro and in vivo [24,25]. Both gemcitabine and
AZD6738 had high CCS scores within the drug library screen (0.53
and 0.60 respectively) indicating high S/G2 specificity, consistent
with their known modes of action. Given the ability of these com-
pounds to synergise and induce replication catastrophe [24,25], we
investigated whether exposure to both compounds would affect the
Figure 2. Compound library screen in G1 or S/G2 accumulated AsPC-1 cells. a. Frequency distribution of CCS scores for each compound tested with a Gaussian curve fitted to
describe the mean (m), standard deviation (s) and goodness of fit (R2). b. CCS score plotted against the minimum AUC value across both conditions (AUCmin). c. Average CCS scores
and AUCmin values when compounds are grouped by pathway as provided by Selleckchem. d-h. Waterfall plots of CCS score by pathway with average DMSO control scores plotted
as the first column. Compound names added numerical order if score was above 1.5s with colour shading representing the CCS score being above 1.5, 2 or 3s.
6 T.I. Johnson et al. / EBioMedicine 68 (2021) 103396CCS score as part of a schedule. To match a typical dosing schedule
given for this combination in vivo [24,25], we added AZD6738 contin-
uously at two fixed doses (0.3 and 1mM) after a 6h gemcitabine pulse
in G1 or S/G2 accumulated cells. Given the limited gap between these
two compounds, as well as the DNA and ribonucleotide reductase
large subunit (RRM) 1 binding mechanisms of gemcitabine [26-29],
this drug schedule, for the purposes of this work, is referred more
generally as a combination although given sequentially. As a single
agent, continuous AZD6738 exhibited a CCS score of -0.04 with a GI50
of 1.99 and 2.76 mM in G1 and S/G2-accumulated cells respectively
indicating that continuous exposure did not demonstrate anyparticular cell cycle phase-dependent sensitivity (Figure 4a). Given
AZD6738 did show S/G2-associated sensitivity as a pulse (Figure 3a),
this is consistent with the fact that cells will lose cell cycle synchro-
nicity over time which renders the initial cell cycle phase irrelevant.
However, we were surprised to observe that the addition of continu-
ous 0.3 mM AZD6738 reduced the concentration of gemcitabine
needed to reach 50% growth inhibition in G1 (1.46 to 0.88 mM) but
not S/G2 (0.39 to 0.34 mM) accumulated cells (Figure 4a). The extent
of growth inhibition across the full range of gemcitabine doses in G1
versus S/G2 was boosted further with 1 mM AZD6738, although this
schedule was highly toxic in both cell cycle conditions (Figure 4a).
Figure 3. Compound dose responses in G1 or S/G2 accumulated AsPC-1 cells. a. Dose response curves of selected compounds with biological triplicates. A non-linear regression
was fitted to each dose response and a GI50 value calculated and reported where appropriate. *= Extrapolated value, where GI50 > 30 mM max concentration tested. b. Average CCS
score of selected compounds as well as the DMSO control. All data are shown as mean § SEM from three independent experiments; for b comparisons between control and each
compound was assessed using a one-way ANOVA with a Bonferroni multiple comparison correction.
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tions that did not appear to reduce cell proliferation as a single agent,
these data supported previous reports of a synergistic relationship
between these two compounds. These data suggested that exposure
to both compounds may be more effective in transiently G1-accumu-
lated cells with increasing concentrations of AZD6738, even though
both compounds have S/G2 specific mechanisms.
Given this finding, we hypothesised that palbociclib, a reversible
CDK4/6 inhibitor, used as a pre-treatment would mimic the transient
G1 accumulation seen after synchronisation and potentiate the
effects of the gemcitabine/AZD6738 combination. MIA PaCa-2 cells
have been shown to be sensitive to the combination in vitro and invivo [24,25], and also demonstrated G1 accumulation after 22 hours
of exposure to palbociclib, with associated decreases in S, G2 and M
phase populations consistent with inhibited S-phase entry (Figure
S6) and positive Rb status (data not shown) and were therefore an
appropriate model to test further.
Given the potency of the combination and the fact that 96-well
assays with low cell numbers are inherently sensitive to both cyto-
toxic and cytostatic effects, we wanted to design an in vitro assay able
to distinguish between these two phenotypes. To achieve this, we
seeded 6-well plates at low density analogous to a colony forming
assay but allowed the cells to form visible colonies before treatment.
This would mean that only large-scale but not small-scale cell death
Figure 4. Transient G1 accumulation increases the cytotoxicity associated with the gemcitabine/AZD6738 combination. a. Dose response curves of gemcitabine, AZD6738 and
combinations where AZD6738 is fixed at either 0.3 or 1mM in G1 or S/G2 accumulated AsPC-1 cells. Gemcitabine was added as a 6h pulse whereas all AZD6738 doses were continu-
ous. A non-linear regression was fitted to each dose response and a GI50 value calculated where appropriate. Cell cycle specificity (CCS) score was calculated for each biological repli-
cate and the mean/standard error included. Scores of>0.2 or<-0.2 are denoted S/G2 or G1-specific respectively. b. Schematic outlining the “clonocidal” assay, a modified clonogenic
assay where treatment of established cell colonies allows identification of truly cytotoxic drug treatments. c. Representative images of MIA PaCa-2 cells after performing the clonoci-
dal assay with 22h pre-treatment with either DMSO or 1 mM palbociclib followed by 6h of 100 nM gemcitabine and continuous 1 mM AZD6738. Colonies were fixed and stained
with sulforhodamine B (SRB) dye before visualisation. d. Quantification of SRB intensity compared to DMSO after assessing the schedule in a clonocidal assay using MIA PaCa-2,
K8484, MCF7 and HeLa cells e. Representative DNA content histograms (top) and gH2AX vs DNA content (bottom) of MIA PaCa-2 cells after respective treatments. f. Quantification
of gH2AX positive cells across each treatment. Palbo. = palbociclib, gem. = gemcitabine. All data are shown as means § SEM (a, d) or SD (f) from three independent experiments.
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and so was subsequently referred to as a “clonocidal” assay. Colonies
were visible roughly 8 days after seeding whereupon they were pre-
treated with 1 mM palbociclib or DMSO for 22h before treatment
with gemcitabine (6h pulse) or AZD6738 (continuous). Significant
colony death was observed after the gemcitabine/AZD6738 combina-
tion but only after palbociclib pre-treatment (Figure 4c) suggesting
G1 accumulation increases the cell death associated with this combi-
nation. In addition, when palbociclib was not removed prior to expo-
sure to gemcitabine/AZD6738 this affect was completely abrogatedand, alongside additional evidence of effective S phase entry after
palbociclib release, suggests the G1 synchronisation effect elicited by
palbociclib is critical for the observed cytotoxicity (Figure S6). We
then tested this schedule in the same assay across three other cancer
cell lines of various cancer types including HeLa cells which are posi-
tive for the E6/E7 human papillomavirus proteins rendering them
insensitive to CDK4/6 inhibition. All cell lines demonstrated increased
colony death after the triple schedule compared to the gemcitabine/
AZD6738 combination alone, apart from HeLa cells confirming that
palbociclib-induced G1 accumulation appears to be responsible for
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had no significant effect on colony number and palbociclib pre-treat-
ment did increase single agent efficacy of gemcitabine in K8484 and
MCF7 cells as well as increase single agent AZD6738 potency in
K8484 cells. Although the differential potency between DMSO and
palbociclib pre-treatment was lost as expected in HeLa cells due to
inactivation of Rb, these cells demonstrated high colony death with
the combination alone suggesting that Rb pathway inactivation may
be increasing sensitivity to this combination.
The gemcitabine/AZD6738 combination has been previously
shown to potently induce markers of DNA damage including those
associated with S phase and replication-associated damage [24,25].
To ascertain the effect of palbociclib pre-treatment prior to this com-
bination on cell cycle and DNA damage we analysed treated MIA
PaCa-2 cells by flow cytometry. DNA content analysis highlighted an
increase in intra-S accumulated cells 24h after the triple schedule
compared to the combination without palbociclib pre-treatment
(Figure 4e). Furthermore, we observed an increase in cells positive
for phospho-H2AX (gH2AX), a broad marker of DNA damage, that
were pre-treated with palbociclib and persisted after 48h suggesting
a lack of DNA repair (Figure 4f). Together, these data suggest that pal-
bociclib pre-treatment leads to an increase in DNA damage and cell
death associated with combined gemcitabine and AZD6738 exposure,
reflecting the changes that we observed when assessing cell cycle
sensitivity scores in synchronised AsPC-1 cells.
Higher CCS scores correlate with drug scheduling antagonism
Although we had investigated utility of the CCS score by candidate
approach using gemcitabine/AZD6738, we also wanted to evaluate
the broader utility of this phenotype. To utilise our CCS score dataset
and assess potential uses for this annotation, we investigated
whether there was any correlation between CCS score and drug
scheduling synergy/antagonism as assessed by Koplev and colleagues
[30]. In their study, the effect of drug sequence (drug A followed by
drug B, and vice versa) within some 10,000 different drug schedules
was assessed in pancreatic cancer cells in a high throughput assay.
Our CCS score was compared with their synergy scores derived using
the PANC-1 cell line, as their AsPC-1 dataset included a much smaller
subset of compounds (Figure 5a). The authors did however note a
good correlation between PANC1 vs AsPC-1 lines, justifying the com-
parison. A total of 1,156 schedules contained compounds that over-
lapped with our library and the synergy score of these (where
>0 = synergistic, <0 = antagonistic) were plotted as a histogram to
determine their distribution (Figure 5b). This compiled dataset con-
tained both antagonistic and synergistic interactions, although the
majority (765/1,156) of these schedules were clustered around a neu-
tral synergy score between -0.05 and 0.05 with neither synergy or
antagonism being observed. To investigate the effect of cell cycle spe-
cificities at the extremes of synergy/antagonism, we interrogated CCS
score using the top 40 antagonistic and synergistic schedules from
the Koplev dataset (Figure 5c). Although no difference was observed
between CCS scores of the first drug (drug A) in antagonistic versus
synergistic schedules, the second drug (drug B) displayed a signifi-
cantly higher CCS score (p=0.001, one-way ANOVA) within antago-
nistic schedules, suggesting that when an S/G2 specific compound is
used as the second drug in a sequence it is more likely to be antago-
nistic (Figure 5c). This association was also true when all the sched-
ules were clustered based on having S/G2 (CCS>0.2) or non-S/G2
(CCS<0.1) scores for drug B (Figure 5d), with average synergy scores
of -0.129 and -0.012 respectively across a total of 1,054 schedules. To
see whether particular drugs were driving this association, we
selected the four most frequent compounds in schedules with a syn-
ergy score of <-0.1 (i.e. antagonistic), doxorubicin, vincristine sul-
phate, paclitaxel and daunorubicin, and directly compared synergy
scores between matched schedules (A->B vs. B->A). They were allfound to have a significantly lower synergy score when used as the
second drug in a schedule (i.e. B->A) and all had been assigned a CCS
score of >0.2 (Figure 5e). In cases where synergy was observed when
these drugs were used as the first compound in the sequence, the
associated second compound had a neutral CCS score (S1237, temo-
zolomide, CCS=-0.06; S2057, cyclophosphamide, CCS=0.02; S1278,
altretamine, CCS=0.01). A notable exception to this correlation
included a synergistic schedule involving the S/G2 associated gemci-
tabine as the second compound (Figure 5c). This effect was observed
when cells were exposed to gemcitabine after, but not before, the
compound lenalidomide (after, synergy score = 0.19; before, synergy
score = 0). These compounds showed promise as a combination in
vitro but failed to offer significant benefits in a clinical trial [31,32].
Overall, these significant associations between drug scheduling
antagonism and CCS score may suggest this annotation has utility in
optimising effective drug combinations.
Discussion
The significant limitations surrounding current synchronisation
methods, namely toxicity, cell yield, time required and cell line vari-
ability, are well known. The benefits of an RO-3306-based method
described in this work could be of value when optimising such tech-
niques in other cell lines. The reduction in toxicity associated with
the RO-3306 shake-off method was critical to ensure unbiased down-
stream analysis within our proliferation-based drug library screen
but may also have important implications for the wider cell cycle
field by potentially reducing spurious off-target effects. The limitation
of this method appears to be the variable level of synchronisation
between different cell lines, a common feature of synchronisation
techniques utilising cell cycle checkpoints.
Overall, the CCS score of hits we identified from the compound
library screen generally matched their known targets such as topo-
isomerase inhibitors for S/G2 and PI3K/mTOR inhibitors for G1, vali-
dating the synchronisation method and providing a platform to
investigate compounds with less well-known mechanisms. We were
also able to identify cases where the CCS score varied despite having
the same molecular target (e.g. TOP1; topotecan = 0.70, SN-38 = 0.38)
as well as identifying a number of compounds that had no apparent
cell cycle specificity despite having high levels of potency (e.g. ispine-
sib = 0.15, kinesin spindle protein inhibitor). Drug potency was one
factor related to generation of CCS scores, although the two were not
significantly correlated. It is possible that use of longer incubation
times may have uncovered more cell cycle dependencies, however
significant overlap with cell cycle transitions could impact on the reli-
ability of the CCS score. The comparison of CCS scores in pulse versus
continuous exposure can also provide insights into drug mode of
action. AZD6738, for example, demonstrated S/G2 associated activity
that was not dramatically shifted by continuous exposure (GI50:
pulse = 5 mM, cont. = 2.4 mM), suggesting transiently inhibiting ATR
in S/G2 cells accounts for a significant proportion of its associated
cytotoxicity. With previous reports of hypersensitivity of ATM-null
cell lines to ATR inhibition [25,33,34], it is possible this effect could
potentially be boosted in cells without functional ATM. This may
explain why others have found AZD6738-induced bone marrow tox-
icity with such tissue types having an abundance of highly prolifer-
ative cells [35]. The inherent lack of AZD6738-induced G1-associated
toxicity, however, may also be exploited in schedules that use tran-
sient CDK4/6 inhibition to protect the bone marrow in patients with
Rb negative tumours [36,37].
Exposure to both gemcitabine and AZD6738 was more productive
in G1-accumulated cells, suggesting a pre-replicative mechanism and
could be exploited using transient CDK4/6 inhibition in a schedule
that appeared Rb-dependent. Of note was the extent of cell death fol-
lowing treatment in the “clonocidal” assay, an adaptation of the col-
ony forming assay, which assesses the extent of treatment cell death
Figure 5. Correlation between CCS score and drug scheduling synergy/antagonism. a. General scheme showing how the synergy/CCS score combined dataset was made using
synergy data generated by Koplev et al26. b. A frequency distribution of synergy scores for the included set of schedules where both compounds have an associated CSS score. c.
Summaries showing median cell cycle score for all drugs alongside the top 40 antagonistic or synergistic schedules. Each point represents a single compound, n=40 and dashed lines
connect two compounds within the schedule. Box inset shows the CCS scores of the synergitic schedule of lenalidomide (S1029) and gemcitabine (C1006) d. Drug schedules were
split into distinct clusters based on whether the second drug in the sequence (Drug B) has a CCS score of <0.1 (not S/G2 specific) or >0.2 (likely to be S/G2 specific) and plotted
against synergy score. Each point represents a single schedule alongside the median value; statistical significance tested using a two-tailed Mann-Whitney t-test. e. Four of the
most common compounds in antagonistic schedules were selected. The synergy score of schedules where each drug is first or second in the sequence was compared. Each data point
is a single schedule of a total (n) of 30 and the dashed line represents the mean; statistical significance tested using a two-tailed Mann-Whitney test. The CCS scores of notable com-
pounds are added for reference. Sample size (n) shown on b and d is the number of independent schedules in that group. Statistical significance tested using either a One-way
ANOVA with a Bonferroni's multiple comparison correction (c) or two-tailed Mann-Whitney test (d and e).
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that the measured effect is less influenced by low seeding densities
but also by compounds that induce cytostatic rather than cytotoxic
effects. Taken together with the increase in intra-S phase of the cell
cycle post-treatment alongside increased gH2AX, a marker of DNA
damage, further work should characterise any replication-mediated
effect of G1 accumulation prior to gemcitabine/AZD6738 treatmentto elucidate the mechanism of action. Given the effect of gemcitabine
and ATR inhibition on ribonucleotide reductase it is possible that the
dual activities of these compounds directly impact on pre-replication
events prior to S phase thereby increasing the affected population
after palbociclib pre-treatment [29,38,39]. Interestingly, the sensitiv-
ity of HeLa cells to the combination without pre-treatment with pal-
bociclib may suggest that Rb pathway loss is a predictive biomarker
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ther investigation. Overall, we demonstrated that a drug treatment
with a G1-associated CCS score showed increased efficacy when com-
bined with a drug that induces G1 accumulation, suggesting that
other drugs with these attributes may also be viable candidates.
Indeed, the utility of combining mTOR inhibitors with palbociclib has
been well validated in vitro and in vivo indicating that CCS score may
be useful in finding effective drug combinations [13-16].
Despite the limitations with respect to cell lines, our correlation
between CCS score in AsPC-1 cells and scheduling data in PANC-1
cells produced by Koplev et al demonstrated that CCS score may also
inform scheduling strategies [30]. Of the 1,156 drug schedules used
in our analysis, the majority (765/1,156) showed neither antagonism
nor synergy (scores between -0.05 and 0.05). Even so, multiple com-
parative analyses suggested that if the second drug in the schedule
had a higher, S/G2-associated CCS score then the schedule is more
likely to be antagonistic. This seemed to be particularly true for
microtubule poisons such as paclitaxel and vincristine where drug
sequence is known to impact anti-tumour efficacy, with this cell
cycle-dependent antagonism also noted by Koplev and colleagues
[30]. Although these analyses are by no means exhaustive, along
with existing published data it contributes to the growing body of
evidence that timing and cell cycle specificity are important aspects
of pre-clinical, in vitro compound profiling studies that could be
incorporated into early stage drug development pipelines.
As a final remark, the clinical complexities of schedules such as
those described here with palbociclib are significant and subsequent
work in vivo should aim to address how this could be implemented
in humans. The importance of these scheduling studies is likely to
increase given the significant interest in DDR inhibitors with recent
evidence highlighting how scheduling of these inhibitors with other
compounds can impact tolerability, a significant issue with this class
of compounds [40]. As the response in HeLa cells demonstrated, the
key consideration for this approach is genetic context and as such
patient stratification and biomarker development will be of para-
mount importance in translating such treatment schedules to clinical
setting.
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